Press Release

FOR IMMEDIATE RELEASE  |  Global Data Route Analytics  |  September 2026

Autoinjectors market projected to expand more than 3.5-fold between 2025 and 2035 as GLP-1 therapies, biologics and biosimilars move into patients' homes; North America leads, Asia-Pacific grows fastest at 14.12% CAGR; 151 companies profiled across 15 chapters.

Global Data Route Analytics today announced the publication of its new study, Global Autoinjectors Market Size, Share, Trends & Forecast 2020–2035. According to the report, the Global Autoinjectors Market was valued at USD 13,451.97 Million in 2025 and is projected to reach USD 48,029.60 Million by 2035, growing at a CAGR of 13.57% over the forecast period. The market stood at USD 8,420.00 Million in 2020.

The 1,750-page report quantifies the market across twelve segmentation axes (device reusability, drug-container architecture, capacity, drive mechanism, dose configuration, connectivity, route of administration, therapy area, drug modality, end-use setting, administrator type and region), covers five regions and 31 countries, includes a dedicated ten-dimension price-analysis chapter and profiles 151 companies across the entire autoinjector value chain.

Key Findings

• North America remains the largest regional market at USD 6,100.47 Million in 2025, rising to USD 21,813.81 Million by 2035, supported by the deepest biologic and GLP-1 prescribing base and mature combination-product regulation.
• Asia-Pacific is the fastest-growing region at a 14.12% CAGR, driven by expanding healthcare infrastructure, rising chronic-disease burden and localised device manufacturing in China and India.
• Single-use / disposable devices generate 97.1% of 2025 revenue, while reusable autoinjector systems are the fastest-growing category at a 14.69% CAGR as circular and electromechanical platforms reach market.
• Monoclonal antibodies and fusion proteins account for roughly 61% of revenue by drug modality; home and self-care settings represent about 68% of revenue by end use.

What Is Driving Growth

Demand is anchored in a chronic-disease base that continues to expand. The IDF Diabetes Atlas counts 589 million adults living with diabetes today, rising to 852.5 million by 2050; the WHO expects the population aged 60 and over to double to 2.1 billion by 2050. The GLP-1 wave has added a second engine: the U.S. FDA resolved the multi-year semaglutide and tirzepatide shortages only once manufacturers demonstrated national-scale device capacity, and WHO added GLP-1 receptor agonists to its Essential Medicines List in 2025. IV-to-subcutaneous conversion in oncology and a growing biosimilar pipeline, with 90 biosimilars now approved in the US, are multiplying autoinjector presentations.

"The autoinjector is no longer an accessory to the drug; it is the constraint on how fast the drug can reach patients," said a senior analyst at Global Data Route Analytics. "Device supply, not molecule supply, is increasingly the bottleneck behind GLP-1 availability, and that is reshaping where capital is being deployed across the value chain."

Restraints and Challenges Analysed

The report also examines the forces working against adoption: high-profile device recalls by the FDA and UK MHRA, pricing scrutiny that runs from the 2016 EpiPen hearings to CMS's negotiated 2027 Medicare price of USD 274 per month for Ozempic against a USD 959 list price, the first needle-free epinephrine nasal spray as a route-of-administration substitute, counterfeit GLP-1 pens entering the legitimate supply chain, and manufacturing-capacity bottlenecks across primary containers, elastomers and assembly.

Companies Profiled

Rather than a short key-players list, the report profiles 151 companies across 15 dedicated chapters, including SHL Medical, Ypsomed, Owen Mumford, Phillips-Medisize, Haselmeier, Nemera, Elcam Medical, Gerresheimer, SMC Ltd., Enable Injections, Credence MedSystems, Crossject, PharmaJet, Novo Nordisk, Eli Lilly, Sanofi, AbbVie, AstraZeneca, UCB, Teva, Kaleo, ALK-Abelló, Celltrion, Samsung Bioepis, Fresenius Kabi, Viatris, West Pharmaceutical Services, BD, SCHOTT Pharma, Nipro, Terumo, Recipharm, Catalent, Vetter Pharma, Jabil Healthcare and Kindeva Drug Delivery, alongside connected-device, safety-syringe, automation and regional emerging-market companies. Each profile covers company details, financials, product summary and recent developments.

Recent developments tracked include SHL Medical's USD 220 million autoinjector manufacturing facility in South Carolina, embecta's acquisition of Owen Mumford, FDA approval of AstraZeneca's Saphnelo Pen, Haselmeier's PiccoJect entering clinical trials, Ypsomed's launch of the YpsoLoop circular platform, and Kindeva's contract worth up to USD 129 million to supply DuoDote autoinjectors to the U.S. Strategic National Stockpile.

Report Scope

About Global Data Route Analytics

Global Data Route Analytics is a market research and consulting firm delivering syndicated and custom research across healthcare, life sciences, medical devices and adjacent industries. Our reports combine primary interviews, verified secondary sources and proprietary estimation models to give manufacturers, investors and policy teams a quantified basis for decisions.

Report: Global Autoinjectors Market Size, Share, Trends & Forecast 2020–2035

Media & Sales Contact: Global Data Route Analytics  |  globaldatarouteanalytics.com/contact